Clinical Trial Update: The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK) [Phase 3]

View source ↗

Summary

The document reports the completion of the intensive pharmacokinetics sub-study ENCORE1-PK connected to the ENCORE1 Phase 3 HIV trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• efavirenz (Sustiva) (efavirenz)

Snippet

Sponsor: Kirby Institute | Conditions: HIV Infection | Phase 3 | Status: COMPLETED